Clinical trial · no report yet · Phase 3
TROPION-LUNG01
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
- NCT04656652 ↗
- Active, not recruiting
- Daiichi Sankyo
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 118 | |
| Podcasts | 81 | |
| YouTube | 79 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- DS-1062a; Docetaxel
- Arms
- DS-1062a 6.0 mg/kg · Experimental
- Docetaxel 75 mg/m^2 · Active comparator
- Enrollment
- 605
- Primary outcomes
- Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel
- Overall Survival (OS) Following DS-1062a Versus Docetaxel
- Sponsor
- Daiichi Sankyo with AstraZeneca
- Start
- Dec 21, 2020
- Primary completion
- May 10, 2024
- Results posted
- Yes
- Registry record
- NCT04656652 · updated Aug 26, 2026
Publications
linked from the registry- Sands J, Ahn MJ. Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study. Future Oncol. 2026 Feb;22(3):271-284. doi: 10.1080/14796694.2025.2586004. Epub 2025 Nov 21. PubMed 41268710
- Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Perol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol. 2025 Nov;20(11):1669-1682. doi: 10.1016/j.jtho.2025.06.002. Epub 2025 Jun 12. PubMed 40516821
- Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Perol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9. PubMed 39250535